Shasun Pharma receives USFDA approval for Carisoprodol Tablets

Carisoprodol is a muscle relaxer and has sales of around $38 million

Shasun Pharmaceuticals has received USFDA approval for Carisoprodol Tablets USP 250 mg and 350 mg.

In an announcement BSE today the company said that Carisoprodol Tablets USP 250 mg and 350 mg has sales of around $38 million, while the 350 mg has few Generic players, Shasun expects to be the first marketed generic player in the $16 million Carisoprodol Tablets 250 mg opportunity.

The company said, the product will be manufactured at the Puducherry facility and will be distributed in US through a partner.

The product is expected to be launched shortly, said the company adding that Carisoprodol is a muscle relaxer that works by blocking pain sensations between the nerves and the brain.

It is used together with rest and physical therapy to treat injuries and other painful musculoskeletal conditions.